NSE: LALPATHLAB | BSE: 539524

Strong Performer, Getting Expensive

Download real time

3017.20 13.20 (0.44%)

31.55% Gain from 52W Low

143.9K NSE+BSE Volume

NSE 23 Jul, 2025 3:31 PM (IST)

25,276.7

Market Cap

Market Runner Up

0.4

Beta 1Year

Very Low volatility

Dr. Lal Pathlabs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LALPATHLAB, BSE:539524 Dr. Lal Pathlabs Ltd.

Search Inside the pdf :

Dr. Lal Pathlabs Ltd.

20 Jul 2025

3017.20

0.44%

FY25 AR: Stable outlook despite leadership transition

Buy: Dr. Lal Pathlabs Ltd.

Emkay

Following the slump in FY23, DLPL has registered revenue/EBITDA/PAT CAGR of 10%/19%/43%, respectively, over the last two years.

Number of FII/FPI investors decreased from 382 to 358 in Jun 2025 qtr

Dr. Lal Pathlabs Ltd.

12 May 2025

3017.20

0.44%

DR. LAL PATH LABS LTD.

Buy: Dr. Lal Pathlabs Ltd.

FundsIndia

Emkay released a Buy report for Dr. Lal Pathlabs Ltd. with a price target of 3100.0 on 20 Jul, 2025.

Dr. Lal Pathlabs Ltd.

26 Apr 2025

3017.20

0.44%

Decent quarter, limited headroom for margins expansion

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q4FY25 results were slightly better than our expectation. Outperformance was driven by higher sample volumes (up 9.5% YoY) and realisation improvement.

Dr. Lal Pathlabs Ltd. is trading above all available SMAs

Dr. Lal Pathlabs Ltd.

26 Apr 2025

3017.20

0.44%

Steady quarter; encouraging outlook

Buy: Dr. Lal Pathlabs Ltd.

Target

Emkay

DLPL reported a steady Q4, with EBITDA beating street/our estimates by 6% and adj PAT improving 34% on YoY basis. Strong performance in core markets (Delhi NCR), buoyed by network expansion, offset the persistent muted performance of Suburban (mid-single digit revenue growth).

Number of FII/FPI investors decreased from 382 to 358 in Jun 2025 qtr

Dr. Lal Pathlabs Ltd.

14 Feb 2025

3017.20

0.44%

DR. LAL PATHLABS LIMITED

Accumulate: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

Dr. Lal Pathlabs Ltd. is trading above all available SMAs

Dr. Lal Pathlabs Ltd.

13 Jan 2025

3017.20

0.44%

DR. LAL PATHLABS LTD.

Sell: Dr. Lal Pathlabs Ltd.

Ventura

Elevated Valuations Dampen Strong Fundamentals

Number of FII/FPI investors decreased from 382 to 358 in Jun 2025 qtr

Dr. Lal Pathlabs Ltd.

24 Oct 2024

3017.20

0.44%

Growth moderates; near term green shoots unlikely

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q2FY25 revenue growth of 9.8% YoY was lower than our expectation, though its better EBITDA margin of 30.7% was a surprise.

Emkay released a Buy report for Dr. Lal Pathlabs Ltd. with a price target of 3100.0 on 20 Jul, 2025.

Dr. Lal Pathlabs Ltd.

22 Aug 2024, 12:00AM

3017.20

0.44%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Recommendation Target

Geojit BNP Paribas

Dr. Lal Pathlabs Ltd. has an average target of 2992.60 from 5 brokers.

Dr. Lal Pathlabs Ltd.

08 Aug 2024

3017.20

0.44%

Steady quarter; valuation a bit pricey

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q1FY25 result was in line with our expectations. Growth was driven by better uptick in Swasthfit (up 26.4% YoY) overall sample volume rose 9.3% YoY.

Dr. Lal Pathlabs Ltd. is trading above all available SMAs

Dr. Lal Pathlabs Ltd.

19 Jun 2024

3017.20

0.44%

Corner Office view: Spotlight on bundling and Suburban ramp up

Buy: Dr. Lal Pathlabs Ltd.

Emkay

We met DLPL’s MD Dr. Om Manchanda to gauge competitive intensity and its strategy to boost volumes. Meeting KTAs are: 1) DLPL is increasingly witnessing the ‘bundling’ phenomenon as doctors are recommending multiple tests to ascertain accurate prognosis.

Dr. Lal Pathlabs Ltd. is trading above all available SMAs

Is Dr. Lal Pathlabs Ltd. worth buying?

226 Votes:

Buy 76.11%

Sell 14.6%

Hold 9.29%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf